当前位置：药药网 / 数据中心 /变体注释摘要_药物剂量、反应、代谢
他克莫司-tacrolimus
变量_单倍型
CYP2C19*1, CYP2C19*2, CYP2C19*3
类型
Dosage,"Metabolism/PK"
记事
in patients receiving co-treatment with voriconazole. This difference is more significant in CYP3A5 *3/*3 (non-expressors). "no patient was found to carry CYP2C19*3/*3 genotype or CYP2C19*17 allele". "the requirement of TAC dose in CYP2C19 IMs/PMs was significant lower than that of EMs in Co-VRC group (p=0.0395) (Figure 4A). The TAC C0/D in CYP2C19 IMs/PMs was markedly higher than that of EMs (p=0.0417) (Figure 4B). Moreover, CYP2C19 genotypes were not associated with the changes of TAC dose and C0/D in both control and Pre-VRC groups"
专家论述
CYP2C19 *1/*2 + *1/*3 + *2/*2 +*2/*3 (assigned as poor metabolizer and intermediate metabolizer genotypes phenotype) is associated with decreased dose of tacrolimus in people with heart transplantation as compared to CYP2C19 *1/*1 (assigned as normal metabolizer genotype phenotype) .
等位基因
*1/*2 + *1/*3 + *2/*2 +*2/*3